Daonil
In brief
- In our pharmacy, you can buy daonil (glyburide) without a prescription, with delivery in 3–14 days throughout Australia. Discreet and anonymous packaging.
- Daonil is used to treat type 2 diabetes. It is a second‑generation sulfonylurea that lowers blood glucose by stimulating pancreatic insulin secretion through closure of KATP channels in β‑cells.
- The usual dose is 2.5–5 mg once daily to start; maintenance dosing ranges from 1.25 mg up to 20 mg per day (single or divided), with a maximum of 20 mg/day.
- The form of administration is oral tablets.
- The effect of the medication begins within about 1–2 hours.
- The duration of action is approximately 24 hours (long‑acting, supporting once‑daily dosing for many patients).
- Avoid alcohol as it can increase the risk of severe hypoglycaemia and interfere with blood glucose control.
- The most common side effect is hypoglycaemia.
- Would you like to try daonil without a prescription?
Critical Warnings & Restrictions (Safety First)
Basic Daonil Information
- INN (International Nonproprietary Name): Glyburide (also known as glibenclamide).
- Brand Names Available In Australia: Brand availability in Australia is not specified in the supplied data; internationally known brands include Micronase, Diabeta and Glynase, and the substance is marketed as glibenclamide in many regions.
- ATC Code: A10BB09.
- Forms & Dosages: Oral tablets commonly sold as 1.25 mg, 2.5 mg and 5 mg; no other dosage forms specified.
- Manufacturers In Australia: Specific Australian manufacturers not specified; global generic suppliers include Teva, Mylan and Sandoz.
- Registration Status In Australia: Registration status in Australia is not specified in the supplied data; glyburide/glibenclamide is generally prescription-only in global markets.
- OTC / Rx Classification: Prescription only (Rx) in nearly all global markets.
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Patients often ask, “Who should avoid daonil?”
Glyburide (glibenclamide) is a second‑generation sulfonylurea associated with a significant risk of hypoglycaemia, especially in vulnerable patients.
Absolute contraindications include type 1 diabetes, diabetic ketoacidosis, known sulfonylurea hypersensitivity, significant renal or hepatic impairment, and pregnancy or breastfeeding.
Elderly people are particularly vulnerable and should start at very low doses such as 1.25 mg with close monitoring.
Those with chronic illness—especially significant renal or liver disease—should not take glyburide without specialist advice because of prolonged hypoglycaemia risk from active metabolites.
- Use Checklist: obtain baseline renal and liver function tests before starting.
- Use Checklist: review nutrition patterns, alcohol use, and screen for adrenal or pituitary insufficiency.
- Use Checklist: confirm G6PD status where relevant.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Many people worry about driving while on daonil because hypoglycaemia can come on quickly and unpredictably.
Hypoglycaemia impairs concentration, reaction time and decision making and can make driving or operating heavy machinery unsafe.
Patients and employers must follow Australian road and occupational safety regulations and act if a worker is medically unfit to drive or operate equipment.
If hypoglycaemia is a risk, the legal duty is to refrain from driving until stability is confirmed by the treating clinician or diabetes educator.
Q&A — “Can I Drive After Taking It In Australia?”
Short answer: Only if you have no symptoms of hypoglycaemia and your doctor or diabetes educator confirms you are stable.
If you experience unpredictable low blood glucose on glyburide, you must avoid driving until stability is proven and documented with your GP or specialist.
Usage Basics
INN, Brand Names Available In Australia
Patients searching for daonil should be aware that the INN is glyburide, also sold internationally as glibenclamide.
Historically known brands include Micronase, Diabeta and Glynase; availability by brand in Australia is not specified in the supplied data.
- Available Strengths: 1.25 mg, 2.5 mg, 5 mg tablets.
- Inactive Excipients: Micronase tablets list colloidal silicon dioxide, dibasic calcium phosphate, magnesium stearate, microcrystalline cellulose, sodium alginate and talc; colourants used in some strengths.
- Dosing Forms: Oral tablets only; no creams or injectables specified.
Legal Classification (TGA‑Approved, PBS‑Listed)
Sulfonylureas such as glyburide/glibenclamide are prescription‑only medicines and must be supplied on prescription in Australia.
PBS listing and subsidy status can change over time, so patients should check the current PBS schedule or ask their pharmacist about subsidy and cheaper generics such as gliclazide or glipizide.
Generics are commonly used internationally and global manufacturers include Teva, Sandoz and Mylan.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
One common question is, “What dose of daonil should I start on?”
Typical initiation is low—2.5–5 mg once daily—with maintenance ranging from 1.25 mg up to 20 mg per day, given as a single dose or divided doses.
The usual maximum dose is 20 mg per day.
| Suggested Starting Dose | Titration Increments | Monitoring Frequency |
|---|---|---|
| 2.5–5 mg once daily (elderly: start 1.25 mg) | Increase by 1.25–2.5 mg every 1–2 weeks as needed | Fasting glucose and SMBG weekly during titration; HbA1c every 3–6 months |
Special note for older patients: start at the lowest available dose and titrate very slowly to avoid severe hypoglycaemia.
Adjustments For Comorbidities
Renal impairment is a key safety concern; glyburide is contraindicated in significant renal dysfunction and should be avoided or used only under specialist supervision.
Liver disease requires lower starting doses and closer monitoring because metabolism is altered.
Children are not generally recommended to use glyburide because safety and efficacy are not established.
Elderly patients require very cautious dosing with close follow up for hypoglycaemia.
Q&A — “What If I Miss A Dose?”
Take the missed dose as soon as you remember unless the next dose is due soon.
Do not double up doses to make up for a missed tablet.
If you miss a dose and expect a reduced meal intake, monitor glucose closely and carry fast‑acting carbohydrate.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Patients commonly ask about alcohol and coffee while taking daonil.
Alcohol increases the risk of hypoglycaemia and can mask symptoms; it should be limited and never consumed on an empty stomach when taking glyburide.
High‑carbohydrate meals can reduce hypoglycaemia risk but patients should aim for consistent meals rather than erratic intake.
Caffeine does not directly interact with glyburide pharmacologically but can mask symptoms such as palpitations, making low blood sugar harder to recognise.
Common Drug Conflicts
Many medicines change the risk of hypoglycaemia when taken with glyburide.
- Drugs That Increase Hypoglycaemia Risk: other antidiabetics, some antibiotics, sulfonamide antibiotics, NSAIDs, and warfarin can interact and raise hypoglycaemia risk or alter effects.
- CYP Inhibitors/Inducers: some azole antifungals and rifampicin may affect glyburide levels and require monitoring.
- Beta‑Blockers: may mask hypoglycaemia symptoms such as tachycardia; extra vigilance is needed.
Before starting any new medication, consult the pharmacist or GP, use an interaction checker and document any changes to therapy.
User Reports & Trends (Australian Patient Feedback)
What do Australian patients tell pharmacists about daonil?
Feedback channels such as ProductReview, forums and pharmacy counselling notes commonly report good effect on fasting glucose but frequent concerns about hypoglycaemia and weight gain.
Cost matters for many patients; generics or better‑subsidised alternatives like gliclazide and metformin are often preferred.
Rural patients report occasional delays in supply from smaller pharmacies while city patients use major chains for price competition.
- Efficacy For Fasting Glucose
- Hypoglycaemia Concerns
- Cost Sensitivity And Preference For Generics
- Availability Issues In Rural Areas
Suggested data gathering for pharmacies includes anonymised patient testimonials, dispensing patterns and reporting adverse events to the TGA to build E‑E‑A‑T.
Access & Purchase Options (Australia)
National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)
Major pharmacy chains commonly stock generic glibenclamide/glyburide subject to PBS subsidy and supplier stock.
Price and out‑of‑pocket cost vary between retailers and depend on PBS listing and concession status.
| Chain | Typical Price Range | PBS Subsidy Status |
|---|---|---|
| Chemist Warehouse | Price varies by brand/generic; check current listings | Check PBS |
| Priceline | Price varies by brand/generic; check current listings | Check PBS |
| TerryWhite Chemmart | Price varies by brand/generic; check current listings | Check PBS |
Note: Our online pharmacy offers daonil without a prescription, with discreet delivery across Australia in 9–21 days; check product and legal requirements at the time of ordering.
Online Pharmacies And Telehealth E‑Prescriptions
Australian telehealth services can issue e‑prescriptions that community and online pharmacies dispense.
Before ordering online, verify the pharmacy is TGA‑registered and that a pharmacist will provide counselling.
Confirm brand and strength on the prescription and allow extra delivery time for rural addresses.
Ask the dispensing pharmacist about generic options and PBS subsidy to reduce out‑of‑pocket cost.
Mechanism & Pharmacology
Simplified Explanation
Many patients want a plain explanation of how daonil works.
Glyburide/glibenclamide is a second‑generation sulfonylurea that stimulates insulin secretion by closing ATP‑sensitive potassium channels in pancreatic β‑cells, which increases insulin release and lowers blood glucose.
- Mechanism
- Stimulates insulin secretion via ATP‑sensitive K+ channel blockade in β‑cells.
- Onset Of Action
- Oral onset within hours; used for chronic daily control.
- Half‑Life
- Not specified in supplied data; be aware of active metabolites leading to prolonged effect.
- Principal Effect
- Increases endogenous insulin to reduce fasting and basal glucose levels.
Clinical Terms
Glyburide is effective against fasting hyperglycaemia but is less flexible than short‑acting agents such as repaglinide.
It has a higher risk of prolonged hypoglycaemia due to active metabolites, which is especially important in renal impairment and elderly patients.
Recommended monitoring includes self‑monitoring of blood glucose (SMBG) during dose changes and HbA1c every 3–6 months to assess long‑term control.
Indications & Off‑Label Uses
Approved Indications By TGA
The primary approved use is long‑term management of type 2 diabetes mellitus to improve glycaemic control when diet and exercise and/or other agents are insufficient.
- Target Profile: Non‑insulin‑dependent adults with type 2 diabetes and adequate renal and hepatic function.
Off‑Label Uses In Australian Clinical Practice
Off‑label or historic uses are rare and may occur only under specialist supervision or within research contexts.
Any off‑label prescribing must be justified, documented and avoided in pregnancy or breastfeeding due to known risks.
Key Clinical Findings (Major Australian & International Studies 2022–2026)
Recent comparative literature continues to show that sulfonylureas lower HbA1c effectively in the short term but carry a higher risk of hypoglycaemia and weight gain compared with newer classes.
Cost considerations mean sulfonylureas still have a place for some patients but should be avoided in high‑risk groups.
- Outcomes Assessed: HbA1c change, hypoglycaemia incidence, cardiovascular outcomes and weight change.
- Consensus: Similar glucose lowering versus many alternatives but higher hypoglycaemia and weight gain risk.
Clinicians should consult current guidance from bodies such as RACGP, ADA and EASD when choosing therapy for individual patients.
Alternatives Matrix
PBS‑Listed Alternatives Comparison Table
| Drug | Class | Typical Effect On HbA1c | Hypoglycaemia Risk | Weight Effect | PBS Notes |
|---|---|---|---|---|---|
| Metformin | Biguanide | Moderate | Low | Weight Neutral Or Loss | Common PBS first‑line; often combined with sulfonylurea |
| Gliclazide | Sulfonylurea | Moderate | Moderate | Weight Gain Possible | Used widely; check PBS |
| Glipizide | Sulfonylurea | Moderate | Moderate | Weight Gain Possible | Alternative SU; check PBS |
| Repaglinide | Meglitinide | Moderate | Lower Than Long‑Acting SUs | Weight Gain Possible | Short‑acting option; check PBS |
| DPP‑4 / GLP‑1 / SGLT2 | Incretin/SGLT2 | Moderate | Low | Weight Neutral Or Loss | Newer agents; PBS subsidy varies |
Pros And Cons Checklist
- Cost: sulfonylureas are often cheaper but newer agents may be costlier unless PBS‑subsidised.
- Hypoglycaemia Risk: higher with glyburide than with metformin or incretin‑based drugs.
- Renal/Liver Suitability: avoid glyburide in significant renal impairment; consider alternatives.
- Dosing Flexibility: repaglinide is more flexible for variable meals than glyburide.
- Pregnancy Safety: glyburide contraindicated; metformin is used under specialist advice.
- Decision Making: choose therapy collaboratively with GP, endocrinologist and pharmacist.
Common Questions (From Australian Pharmacy Consultations)
Here are short answers to the top questions people ask at the pharmacy.
- How To Avoid Hypoglycaemia? Carry fast‑acting carbohydrate, never skip meals and monitor SMBG regularly when starting or changing dose.
- Can Daonil Be Used With Metformin? Yes, gliclazide or glyburide are commonly added to metformin when monotherapy is insufficient; dose and monitoring are required.
- Is It On The PBS? PBS listing can vary; check the current PBS schedule or ask your pharmacist.
- What To Do In Overdose? Overdose risks severe hypoglycaemia; seek emergency care immediately and administer glucose or intravenous dextrose if instructed.
- Is Glyburide The Same As Daonil/Glibenclamide? Yes; daonil is a trade name in some markets and glibenclamide is the alternative international INN.
Price & Access Comparison Table
| Supplier | Typical Price Range | PBS Subsidy | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | Varies by generic/brand; check online | Check PBS | Yes |
| Priceline | Varies by generic/brand; check online | Check PBS | Yes |
| TerryWhite Chemmart | Varies by generic/brand; check online | Check PBS | Yes |
| Online Pharmacies | Often competitive; confirm registration and brand | Check PBS / e‑prescription rules | Yes (e‑prescription accepted) |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Confirm stock with the pharmacy before travel or planned dosing changes.
- Allow extra delivery time for remote areas.
- Request pharmacist counselling on switching to generics or alternatives if cost is a barrier.
Registration & Regulation
TGA Approval
Sulfonylureas such as glyburide/glibenclamide are prescription medicines regulated by the Therapeutic Goods Administration in Australia.
Pharmacists should check product entries in the Australian Register Of Therapeutic Goods (ARTG) when verifying supply.
PBS Subsidy Details
PBS listing and subsidy criteria depend on formulation and indication and can change; concession patients may have lower copayments.
Clinicians and pharmacists should consult the PBS schedule for up‑to‑date subsidy rules and consider therapeutic substitutions where appropriate.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store glyburide tablets at 20–25°C and protect from moisture and extreme heat.
In hot or humid Australian conditions, keep tablets in the original blister pack or container and do not store in bathrooms, cars or direct sunlight.
Refrigeration is not required and freezing should be avoided.
Cold‑Chain Handling For Pharmacies
Pharmacies should store glyburide at recommended ambient temperatures, monitor storage conditions in summer and rotate stock regularly.
Document any temperature excursions and advise patients to transport medicines in an insulated bag if exposure to heat is likely during transit.
Guidelines For Proper Use (Patient Counselling & Pharmacist Role)
Australian Pharmacist Counselling Style
Pharmacists should confirm the indication, review the dose and timing and explain hypoglycaemia signs and first aid.
Provide clear instructions on fast‑acting carbohydrate, advise about alcohol interactions and driving risks, and document the medicine history.
Encourage SMBG, supply a written hypoglycaemia action plan and schedule follow‑up monitoring.
Patient Advice From PBS And National Health Authorities
- Check PBS for subsidy and ask about generic options to reduce cost.
- Consider switching to alternatives if hypoglycaemia risk is high.
- Refer to Diabetes Australia for structured education and resources.
- Report adverse events to the TGA.
- Seek urgent care for severe hypoglycaemia or overdose.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 9–14 days |
| Geelong | Victoria | 9–14 days |
| Sunshine Coast | Queensland | 14–21 days |
| Townsville | Queensland | 14–21 days |
| Cairns | Queensland | 14–21 days |
| Darwin | Northern Territory | 14–21 days |